<DOC>
	<DOCNO>NCT00114101</DOCNO>
	<brief_summary>This randomized phase III trial study lenalidomide see well work compare placebo treat patient multiple myeloma undergo autologous stem cell transplant . Giving chemotherapy peripheral blood stem cell transplant help kill cancer cell body help make room patient 's bone marrow new blood-forming cell ( stem cell ) grow . After treatment , stem cell collect patient 's blood store . More chemotherapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy . Biological therapy , lenalidomide , may stimulate suppress immune system different way stop cancer cell grow . Giving lenalidomide autologous stem cell transplant may effective treatment multiple myeloma .</brief_summary>
	<brief_title>Lenalidomide Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine efficacy CC-5013 ( lenalidomide ) prolonging time disease progression patient multiple myeloma autologous stem cell transplant ( ASCT ) . SECONDARY OBJECTIVES : I . To determine CC-5013 increase complete response ( CR ) rate patient multiple myeloma follow ASCT . II . To compare progression-free survival ( PFS ) overall survival ( OS ) patient multiple myeloma undergone ASCT randomize either CC-5013 placebo . III . To determine feasibility long-term administration CC-5013 multiple myeloma patient undergone ASCT . OUTLINE : PERIPHERAL BLOOD STEM CELL ( PBSC ) MOBILIZATION : Mobilization autologous PBSC perform accord institutional guideline . AUTOLOGOUS PBSC TRANSPLANTATION ( PBSCT ) : Patients receive melphalan intravenously ( IV ) 30-60 minute day -2 -1 2 day day -3 -2 -2 -1 . Patients undergo autologous PBSCT day 0 . Patients randomize 1 2 maintenance treatment arm . ( Note : As 12/17/09 , patient randomize lenalidomide placebo . Patients randomize 12/17/09 assigned lenalidomide . ) ARM I : Beginning day 100-110 , patient receive lenalidomide orally ( PO ) daily . ARM II : Beginning day 100-110 , patient receive placebo ( PO ) daily . In arm , treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year every 6 month thereafter .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<criteria>Patients must active multiple myeloma require treatment ( DurieSalmon stage &gt; = 1 ) stable disease responsive least 2 month induction therapy ; patient smolder myeloma eligible unless disease progress &gt; = stage 1 No 12 month prior therapy , include CC5013 thalidomide Within 12 month initiation induction therapy No prior progression initial therapy ; addition , two regimen allow exclude dexamethasone alone No prior peripheral blood , bone marrow , solid organ transplant Patients must peripheral blood stem cell collection &gt; = 2 x 10^6 cluster differentiation ( CD ) 34+ cells/kg ( patient body weight ) preferably 5 x 10^6 cells/kg ( patient body weight ) ; stem cell may collect time prior transplant ; peripheral blood stem cell collection may occur registration Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Patients must diffuse capacity lung carbon monoxide ( DLCO ) &gt; 50 % predict symptomatic pulmonary disease Patients must leave ventricular ejection fraction ( LVEF ) &gt; = 40 % multi gated acquisition scan ( MUGA ) echocardiogram Patients must uncontrolled diabetes mellitus Patients must active serious infection Patients must human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBSag ) , hepatitis ( Hep ) C positive Patients must nonpregnant nonnursing ; woman childbearing potential must negative serum urine pregnancy test sensitivity least 25 mIU/mL 1014 day prior registration repeat within 24 hour prior first dose lenalidomide ; addition , woman childbearing potential take lenalidomide must pregnancy test perform doctor weekly first 4 week treatment , every 4 week menses regular every 2 week menses irregular , 30 day follow last dose lenalidomide ; woman childbearing potential must either commit continued abstinence heterosexual intercourse begin two acceptable method birth control one highly effective method ( intrauterine device [ IUD ] , hormonal , tubal ligation , partner 's vasectomy ) , one additional effective method ( latex condom , diaphragm , cervical cap ) time , least 4 week begin lenalidomide therapy ; `` woman childbearing '' potential define sexually mature woman undergone hysterectomy menses time precede 24 consecutive month ; men must agree father child must use latex condom sexual contact woman childbearing potential take lenalidomide 4 week therapy stop , even undergone successful vasectomy Absolute neutrophil count ( ANC ) &gt; = 1000/uL Platelets &gt; = 100,000/uL Creatinine clearance* &gt; = 40 cc/min To calculate method CockcroftGault 24hour urine collection Creatinine = &lt; 2 mg/dL Total bilirubin = &lt; 2 mg/dL Aspartate aminotransferase ( AST ) = &lt; 3 x upper limit normal Alkaline phosphatase = &lt; 3 x upper limit normal Urine ( U ) human chorionic gonadotropin ( HCG ) serum HCG negative ( patient childbearing potential )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>